J&J Creates ONE China OTC As Country’s Largest Consumer Health Firm
This article was originally published in The Tan Sheet
Merging Shanghai Johnson & Johnson and Xian Janssen business divisions makes ONE China OTC the largest consumer health care product company in China. The move “is part of a broader Johnson & Johnson strategic initiative to leverage the company’s breadth and scale in China,” says Mike Hsu, ONE China OTC general manager.
You may also be interested in...
China is a major emerging market for J&J’s pharma, medical and consumer health businesses and the planned spinout of the consumer business is likely to allow the US giant to focus on key new drugs in a fast-changing and competitive market while retaining medtech growth. But the consumer sector will continue to face challenges and might learn from similar moves by other multinationals in China.
Multinational cold and cough OTC products have suffered a serious setback in China, as government restricts usage of drugs containing pseudoephedrine.
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.